DNLI News and Press, Denali Therapeutics Inc. From 03/20/25

2025-03-20 14:16:45 ET Summary Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, wit...

2025-03-20 01:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-03-12 23:56:16 ET Summary Baker Brothers' 13F portfolio value decreased from $9.65B to $9.36B, with 26 significant positions making up the majority of the portfolio. The top five holdings—Incyte, BeiGene, ACADIA Pharma, Madrigal Pharma, and Insmed—constitute app...

2025-03-09 06:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2025-02-28 16:54:15 ET More on Denali Therapeutics Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome Denali ALS candidate fails in key study ...

2025-02-27 16:47:01 ET More on Denali Therapeutics Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains Denali Therapeutics gets FDA breakthrough therapy designation for its treatment of hunter syndrome Denali ALS candidate fails in key study ...

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights. “In 2024, we made significant strides across our portfolio,...

ASM International NV New York Shares (ASMIY) is expected to report $3.98 for Q4 2024 Sezzle Inc. (SEZL) is expected to report $3.12 for Q4 2024 Fresenius SE & Co. KGaA ADR (FSNUY) is expected to report for Q4 2024 OraSure Technologies Inc. (OSUR) is expected to report $-0.06 for Q...

Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behavior Long-term safety data with median follow-up of two years, and out to more than four years, d...

2025-01-30 17:06:04 ET Summary Voyager Therapeutics, Inc.'s TRACER platform shows strong preclinical results for BBB-crossing gene therapies, securing multi-billion dollar deals with Novartis and Neurocrine, but lacks clinical trial data. VY7523, a monoclonal antibody for early Al...